Coding

Part:BBa_K4165152

Designed by: Salma Sobhy Sadek   Group: iGEM22_CU_Egypt   (2022-09-30)
Revision as of 13:50, 6 October 2022 by M Zaki (Talk | contribs)


ISAD1 Peptide

Tau binding peptide targeting the PHF seed of Tau

Usage and Biology

ISAD1 peptide with amino acid sequence of SVFKLSLTDAAS. It acts as an inhibitor for wild type full length tau aggregation.

Dry Lab

Modeling

ISAD1 is modeled by AlphaFold2, Apptest, ITASSER, best model obtained from Apptest. 


                            Figure 1.: Predicted 3D structure of Synthetic peptide ISAD1.


Table 1: Quality assessment parameters of ISAD1 model.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


References

1. Aillaud, I., Kaniyappan, S., Chandupatla, R. R., Ramirez, L. M., Alkhashrom, S., Eichler, J., ... & Funke, S. A. (2022). A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro. Alzheimer's research & therapy, 14(1), 1-19.


[edit]
Categories
Parameters
None